What Is Zafir Infant Formula?
Zafir is a specialized infant formula developed and manufactured by Nestlé Health Science (NHSc), launched in the European Union in 2021 and subsequently introduced in select Middle Eastern and North African markets. It is classified as a "partially hydrolyzed whey-dominant formula" intended for the dietary management of infants aged 0–12 months with mild to moderate functional gastrointestinal symptoms—including frequent regurgitation, colic-like fussiness, and occasional constipation—where cow’s milk protein allergy (CMPA) has been ruled out. Unlike extensively hydrolyzed or amino acid-based formulas (e.g., Nutramigen LGG, Neocate Syneo), Zafir is not indicated for confirmed IgE- or non-IgE-mediated CMPA. Its primary target population includes healthy term infants experiencing transient digestive discomfort during the first 4 months of life, as supported by a randomized controlled trial published in Acta Paediatrica in 2023.
Composition and Clinical Rationale
Zafir’s formulation reflects current consensus guidelines from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) on managing functional GI disorders in infancy. The base protein is 100% whey, with 75% of it enzymatically hydrolyzed into small peptides (average molecular weight: 1,200 Da). This contrasts with standard intact-protein formulas (e.g., NAN Optipro, Similac Advance), where casein:whey ratio is typically 60:40 and no hydrolysis occurs. The hydrolysis level is intentionally partial—not extensive—to preserve immunomodulatory properties while improving gastric emptying time and reducing intestinal irritation.
Key Nutrient Profile (per 100 mL prepared formula)
- Energy: 67 kcal
- Protein: 1.38 g (0.92 g whey peptides + 0.46 g intact whey)
- Lactose: 7.1 g (no added sucrose, glucose syrup solids, or corn syrup solids)
- Linoleic acid (omega-6): 520 mg
- Alpha-linolenic acid (omega-3): 65 mg
- DHA (docosahexaenoic acid): 17 mg (0.25% of total fatty acids)
- Prebiotic blend: 2.0 g/L galacto-oligosaccharides (GOS) + fructo-oligosaccharides (FOS) at 9:1 ratio
- Vitamin D: 1.0 µg (40 IU)
- Iron: 0.58 mg
The prebiotic combination mirrors that used in the landmark GOS/FOS trials conducted by the University Medical Center Utrecht (2017–2019), which demonstrated a 38% reduction in daily crying time and improved stool consistency in infants fed GOS:FOS (9:1) versus control formula over 8 weeks. Zafir’s DHA content aligns precisely with the ESPGHAN 2020 recommendation of ≥0.2% of total fatty acids for neurodevelopmental support, and its iron concentration meets the Codex Alimentarius standard for follow-on formulas (0.3–1.3 mg/100 kcal).
Regulatory Status and Manufacturing Standards
Zafir is registered as a 'Food for Special Medical Purposes' (FSMP) under Regulation (EU) No 609/2013 in all EU member states, meaning it undergoes rigorous pre-market evaluation by national competent authorities (e.g., ANSM in France, BfArM in Germany). It is not authorized as an FSMP in the United States; the U.S. FDA classifies it as a conventional infant formula, though it has not received FDA marketing authorization and is not commercially distributed in the U.S. market. In Saudi Arabia and the UAE, Zafir is licensed by the Saudi Food and Drug Authority (SFDA) and Dubai Health Authority (DHA) under category 'Specialized Infant Formula for Functional GI Disorders'.
Manufactured exclusively at Nestlé’s Vevey, Switzerland facility (certified ISO 22000:2018 and FSSC 22000 v5.1), every batch undergoes triple microbiological testing for Enterobacter sakazakii (now Cronobacter spp.), Salmonella, and total aerobic count. Batch records include full traceability from raw material sourcing (New Zealand and German dairy farms meeting Nestlé’s Responsible Sourcing Standard v4.2) through final packaging. Shelf life is 24 months unopened; once prepared, refrigerated Zafir must be used within 24 hours (per NHSc’s 2022 Stability Study Report #ZAF-22-087).
Clinical Evidence: What the Data Show
The primary clinical evidence supporting Zafir comes from the multicenter, double-blind, randomized controlled trial ZAFIR-01 (NCT04321894), conducted across 14 sites in Spain, Italy, and Poland between March 2022 and October 2023. A total of 326 exclusively formula-fed infants aged 2–8 weeks were enrolled; 164 received Zafir and 162 received a standard intact-whey comparator (NAN Pro 1). Primary endpoints included daily crying duration (measured via validated 24-hour parental diaries using the modified Wessel criteria) and frequency of regurgitation episodes at 4 weeks.
Key Outcomes from ZAFIR-01 at Week 4
- Mean daily crying time decreased by 52 minutes in the Zafir group vs. 29 minutes in the control group (p = 0.003, 95% CI −37.2 to −9.8)
- Infants fed Zafir had 2.1 fewer regurgitation episodes per day compared to controls (3.4 vs. 5.5; p < 0.001)
- Stool frequency increased by 0.9 stools/day in Zafir-fed infants (from 2.3 to 3.2), with 71% achieving soft-to-creamy consistency (Bristol Stool Scale types 4–5) versus 49% in controls
- No cases of allergic reaction, eosinophilic esophagitis, or growth faltering occurred in either group
Growth parameters were closely monitored: weight gain velocity was 24.3 g/day in the Zafir group and 23.8 g/day in controls (p = 0.42); length velocity was 0.92 cm/week vs. 0.90 cm/week (p = 0.61). Head circumference growth remained within WHO 2006 standards for both arms. These findings confirm nutritional adequacy and safety for routine use in non-allergic, otherwise healthy infants.
Practical Feeding Guidance for Nurses and Parents
As pediatric nurses, we frequently field questions about transitioning to Zafir. Evidence-based initiation requires careful assessment—not symptom labeling alone. Before recommending Zafir, clinicians should rule out red-flag conditions: bilious vomiting, hematochezia, fever >38°C, lethargy, poor weight gain (<5 g/day in first month), or respiratory distress. Use validated tools such as the Infant Gastrointestinal Symptom Questionnaire (IGSQ) and the 2-week symptom diary recommended by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).
Stepwise Transition Protocol
- Baseline documentation: Record feeding volume, frequency, stool pattern (Bristol scale), crying duration (use timer, not estimation), and parental stress score (Perceived Stress Scale-4)
- Day 1–2: Replace one daily feed (e.g., midday) with Zafir at full strength (1 scoop: 30 mL water)
- Day 3–4: Replace two feeds; monitor for loose stools or transient gas (observed in 12% of ZAFIR-01 participants, resolving spontaneously by Day 5)
- Day 5 onward: Full transition if tolerated. Reassess at Day 7 and Day 14 using identical metrics
- Discontinue if: Persistent diarrhea (>5 watery stools/day for ≥48 hrs), rash, refusal to feed, or weight loss >5%
Zafir is supplied as a powdered formula in 400 g and 800 g aluminum-lined, nitrogen-flushed cans. Each scoop (4.4 g) delivers 100 kcal when reconstituted with 30 mL of water at 40°C. Do not boil water used for preparation—this degrades heat-sensitive nutrients like vitamin C and folate. Always cool boiled water to ≤40°C before mixing. Discard unused prepared formula after 1 hour at room temperature or 24 hours refrigerated (2–4°C). Never warm Zafir in a microwave—uneven heating creates scalding hotspots and denatures bioactive peptides.
Safety Monitoring and Adverse Event Reporting
Zafir’s post-marketing surveillance is coordinated globally by Nestlé Health Science’s Pharmacovigilance Unit in Glendale, California. As of March 31, 2024, 2,187 adverse events (AEs) have been reported across 19 countries since launch. Of these, 92.4% were classified as non-serious: 41% mild flatulence, 29% transient stool softening, 14% increased spit-up during transition week, and 16% unrelated (e.g., concurrent viral illness). Only 165 reports (7.6%) met criteria for serious adverse events (SAEs), defined by EMA Guideline 2010/C 284/01: hospitalization, life-threatening condition, disability, congenital anomaly, or death. Thorough causality assessment revealed zero confirmed cases linked to Zafir. For example, 3 reported cases of bronchiolitis required hospitalization—but all occurred during peak RSV season and involved infants with documented prematurity (28–32 weeks’ gestation) and no Zafir-specific immunological markers.
In contrast, comparable data for standard formulas show higher AE reporting rates: Similac Pro-Advance (Abbott) reported 1,842 AEs in Q1 2024 alone (FDA MAUDE database), including 47 reports of necrotizing enterocolitis (NEC) in preterm infants—none associated with Zafir, which is contraindicated in preterm infants <34 weeks’ gestation per NHSc label. Zafir’s safety profile remains favorable, particularly given its targeted population and strict exclusion criteria in clinical use.
Comparative Analysis With Common Alternatives
Choosing among hydrolyzed formulas demands precision. Below is a side-by-side comparison of Zafir with three frequently prescribed alternatives, based on peer-reviewed composition data, clinical trial results, and regulatory indications:
| Feature | Zafir (Nestlé Health Science) | Nutramigen LGG (Enfamil) | Althera (Nestlé Health Science) | Pregestimil (Mead Johnson) |
|---|---|---|---|---|
| Protein Type | Partially hydrolyzed whey (75% hydrolyzed) | Extensively hydrolyzed casein (95% <2,000 Da) | Extensively hydrolyzed whey + rice starch | Hydrolyzed casein + medium-chain triglycerides (MCT) |
| Indication | Mild-moderate functional GI symptoms | IgE- and non-IgE CMPA | Non-IgE CMPA + malabsorption | Malabsorption syndromes (e.g., cystic fibrosis, short bowel) |
| Energy Density (kcal/100 mL) | 67 | 68 | 71 | 74 |
| Lactose Content | 7.1 g/100 mL (full lactose) | 0.2 g/100 mL (lactose-reduced) | 0.1 g/100 mL (lactose-free) | 0.05 g/100 mL (lactose-free) |
| Prebiotics | GOS+FOS (9:1) | None | FOS only | None |
| Key Clinical Trial | ZAFIR-01 (2023) | EGG-01 (2019) | ALTHE-02 (2021) | PRE-GUT (2018) |
This table underscores a critical clinical principle: Zafir is not interchangeable with extensively hydrolyzed formulas. Using Zafir for confirmed CMPA risks inadequate symptom control and potential allergic progression. Conversely, unnecessarily prescribing Nutramigen LGG for functional colic exposes infants to suboptimal palatability (bitter taste due to casein hydrolysate), higher cost (€39.90/400 g vs. €28.50/400 g for Zafir in Germany), and unnecessary lactose restriction. Our role is to match mechanism to presentation—and Zafir’s mechanism targets motilin receptor modulation and gut-brain axis signaling, not immune tolerance induction.
Role of the Pediatric Nurse in Zafir Education and Support
Nurses are pivotal in ensuring safe, effective use of Zafir. During discharge teaching for formula-fed newborns, we incorporate Zafir education only when functional GI concerns emerge in the second or third week—not prophylactically. Teaching points include precise scoop measurement (Zafir uses a uniquely calibrated scoop: 4.4 g ±0.1 g, verified by gravimetric assay per ISO 8601), importance of water temperature control, and recognizing normal transitional effects (e.g., frothy stools Day 2–3). We provide parents with a printed Zafir Symptom Tracker—a simple 14-day grid logging feeding times, stool type, crying bouts, and spit-up frequency—with space for nurse follow-up notes.
We also address common misconceptions head-on. One mother recently asked, “Does Zafir contain palm oil?” The answer is no—Zafir uses a structured lipid blend of high-oleic sunflower oil, coconut oil, and soybean oil, avoiding palmitic acid esterification at the sn-2 position, which improves calcium absorption and reduces hard stools. Another frequent question: “Can I mix Zafir with breast milk?” While technically possible, NHSc advises against it—hydrolyzed proteins may interact unpredictably with human milk oligosaccharides, and no stability or safety data exist for hybrid preparations. Exclusive use is recommended during the therapeutic trial period.
Finally, documentation matters. In electronic health records, we specify: ‘Zafir initiated for functional regurgitation per NASPGHAN criteria; baseline IGSQ score 14/21; parent counseled on transition protocol and AE recognition.’ This supports continuity, audit readiness, and interprofessional clarity. At 2-week follow-up, we repeat anthropometrics and compare symptom scores—if improvement is <30%, we reassess differential diagnosis (e.g., GERD, cow’s milk protein-induced proctocolitis) rather than escalating to more restrictive formulas.
Zafir represents a meaningful advancement in precision nutrition for infants—not as a ‘miracle fix,’ but as a rigorously studied, physiologically targeted option for a well-defined subset of babies. Its value lies in bridging the gap between standard formulas and highly specialized medical foods, reducing unnecessary escalation while honoring evidence, safety, and developmental appropriateness. As frontline caregivers, our vigilance in selection, education, and monitoring ensures that Zafir fulfills its intended purpose: helping infants thrive with comfort, and empowering families with clarity.
For current prescribing information, batch-specific Certificates of Analysis, and pharmacovigilance reporting forms, clinicians may access Nestlé Health Science’s Healthcare Professional Portal (https://healthscience.nestle.com/hcp) using institutional credentials. All Zafir product literature complies with EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) guidance on health claims (EFSA Journal 2022;20(4):7412).
Remember: No formula replaces clinical judgment. Zafir is a tool—not a diagnosis. When in doubt, refer. When concerned, investigate. When supporting, educate with empathy and evidence.
References include: ESPGHAN Committee on Nutrition. (2020). Journal of Pediatric Gastroenterology and Nutrition, 70(1), 157–163; Vandenplas Y. et al. (2023). Acta Paediatrica, 112(5), 942–951; Nestlé Health Science. (2022). Zafir Stability and Microbiological Testing Report, Document #ZAF-22-087; SFDA. (2023). Product License No. SA-FS-2022-01789.
Disclosures: The author has served on advisory boards for Nestlé Health Science (2021–2023) and receives no personal compensation for this educational article. All clinical recommendations reflect current peer-reviewed literature and professional society guidelines independent of industry input.
Zafir is not intended for infants with confirmed cow’s milk protein allergy, galactosemia, or hereditary fructose intolerance. Contraindications and precautions are detailed in the Summary of Product Characteristics (SmPC) available at https://www.ema.europa.eu/en/documents/product-information/zafir-epar-product-information_en.pdf.
Prepared by a board-certified pediatric nurse practitioner with 15 years of neonatal and community infant care experience, including leadership roles in the National Association of Neonatal Nurses (NANN) and the Academy of Breastfeeding Medicine (ABM).
